Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME study of Nivegacetor (RO7269162) in healthy males
NCT06733298Phase 1Completed
- Sponsor
- Roche
- Start
- Jan 2025
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivegacetor in Alzheimer's disease (AD), sponsored by Roche. Primary endpoints: [14C] recovery in urine, [14C] recovery in feces and 4 more. Started Jan 2025; status: completed.
02
Drugs
nivegacetor
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06733298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06733298.